Ameriprise Financial Inc. Cuts Stock Position in Becton, Dickinson and Company $BDX

Ameriprise Financial Inc. cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,801,454 shares of the medical instruments supplier’s stock after selling 171,290 shares during the period. Ameriprise Financial Inc.’s holdings in Becton, Dickinson and Company were worth $412,627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northcape Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after buying an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC grew its stake in Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 53 shares during the period. Brady Family Wealth LLC grew its stake in Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock worth $989,000 after acquiring an additional 53 shares during the period. Diversified Trust Co raised its holdings in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after acquiring an additional 53 shares during the last quarter. Finally, REAP Financial Group LLC lifted its stake in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $196.4380 on Friday. The business has a 50-day moving average of $180.10 and a two-hundred day moving average of $195.89. The firm has a market capitalization of $56.31 billion, a PE ratio of 35.33, a P/E/G ratio of 1.49 and a beta of 0.20. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the company posted $3.50 EPS. The company’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the company’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company’s stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares in the company, valued at $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock valued at $579,206 over the last 90 days. Corporate insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on BDX. The Goldman Sachs Group downgraded Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Stifel Nicolaus lowered their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.